Analysts Set Expectations for Immunome FY2024 Earnings

Immunome, Inc. (NASDAQ:IMNM - Free Report) - Equities research analysts at Lifesci Capital issued their FY2024 EPS estimates for Immunome in a report released on Tuesday, March 11th. Lifesci Capital analyst C. Zhu expects that the company will post earnings of ($1.83) per share for the year. Lifesci Capital has a "Outperform" rating and a $20.00 price objective on the stock. The consensus estimate for Immunome's current full-year earnings is ($2.21) per share. Lifesci Capital also issued estimates for Immunome's Q4 2024 earnings at ($0.43) EPS.

Separately, Wedbush reiterated an "outperform" rating and set a $33.00 target price on shares of Immunome in a report on Monday, March 10th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome has a consensus rating of "Buy" and a consensus target price of $27.17.

Immunome Stock Performance

Immunome stock traded down $0.68 during midday trading on Friday, hitting $8.36. 609,987 shares of the company's stock were exchanged, compared to its average volume of 809,601. Immunome has a 12 month low of $8.34 and a 12 month high of $26.70. The firm has a 50-day moving average of $9.93 and a two-hundred day moving average of $11.71. The company has a market cap of $666.94 million, a PE ratio of -1.03 and a beta of 1.93.

Hedge Funds Weigh In On Immunome

Hedge funds and other institutional investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. raised its position in Immunome by 217.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company's stock worth $6,469,000 after buying an additional 302,916 shares during the last quarter. Victory Capital Management Inc. raised its position in Immunome by 48.1% during the 3rd quarter. Victory Capital Management Inc. now owns 730,785 shares of the company's stock worth $10,684,000 after buying an additional 237,497 shares during the last quarter. Geode Capital Management LLC raised its position in Immunome by 13.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company's stock worth $17,657,000 after buying an additional 144,557 shares during the last quarter. Magnus Financial Group LLC raised its position in Immunome by 107.8% during the 4th quarter. Magnus Financial Group LLC now owns 53,536 shares of the company's stock worth $569,000 after buying an additional 27,777 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its position in Immunome by 22.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company's stock worth $6,881,000 after buying an additional 85,580 shares during the last quarter. 44.58% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Activity at Immunome

In related news, CEO Clay B. Siegall acquired 150,000 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The stock was purchased at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the transaction, the chief executive officer now directly owns 669,636 shares of the company's stock, valued at $5,189,679. This trade represents a 28.87 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 8.60% of the stock is currently owned by insiders.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.